Italian evidence-based recommendations for the management of ankylosing spondylitis: The 3E Initiative in rheumatology

Clinical and Experimental Rheumatology

Volumn 26, Issue 6, 2008, Pages 1005-1011

  D'Angelo, Salvatore ^a   Padula, Angela ^a   Nigro, Angelo ^a   Cantini, Fabrizio ^b   Matucci Cerinic, Marco ^c   Modena, Vittorio ^d   Punzi, Leonardo ^e   Salvarani, Carlo ^f   Scarpa, Raffaele ^g   Olivieri, Ignazio ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Rheumatology Unit of the 2nd Division of Medicine of Prato Hospital   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Rheumatology Unit   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Ankylosing spondylitis; Evidence based; Expert opinion; Management; Recommendations

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ENTERITIS; ENTHESITIS; EVIDENCE BASED PRACTICE; GENERAL PRACTITIONER; HUMAN; INFORMATION RETRIEVAL; ITALY; LOW BACK PAIN; MEDICAL EXPERT; MEDLINE; PATIENT CARE; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE;

DELPHI TECHNIQUE; EVIDENCE-BASED MEDICINE; HUMANS; ITALY; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING;

EID: 59149101278     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. SIEPER J, BRAUN J: Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
2. SALAFFI F, DE ANGELIS R, GRASSI W: Prevalence of musculoskeletal conditions in a Italian population sample: Results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
3. BRANDT J, MARZO-HONTEGA H, EMERY P: Ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol 2006; 20: 559-70.
4. DAVIDOFF F, CASE K, FRIED PW: Evidence-Based Medicine: Why all the fuss? Ann Intern Med 1995; 122: 727.
5. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
6. SIDIROPOULOS PI, HATEMI G, SONG IH et al.: Evidence-based recommendations for the management of ankylosing spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008; 47: 355-61.
7. BRAUN J, DAVIS J, DOUGADOS M et al.: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.
8. SHEKELLE PG, WOOLF SH, ECCLES M et al.: Clinical guidelines: developing guidelines. BMJ 1999; 318: 593-6.
9. CALIN A, KAYE B, STERNBERG M et al.: The prevalence and nature of back pain in an industrial complex: A questionnaire and radiographic and HLA analysis. Spine 1980; 5: 201-5.
10. HOLLOW M, FISCHER T, REIßHAUER H et al.: Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59: 135-40.
11. SIEPER J, RUDWALEIT M: Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 2005; 64: 659-63.
12. VAN DER HEIJDE D, BELLAMY N, CALIN A et al.: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997; 24: 2225-9.
13. AMOR B, SANTOS RS, NAHAL R et al.: Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21: 1883-7.
14. RUDWALEIT M, BARALIAKOS X, LISTING J et al.: The course of radiographic spinal lesions in patients with early ankylosing spondylitis over a 2-year follow-up period. Ann Rheum Dis 2005; 64 (Suppl. III): 335.
15. MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766-73.
16. GOSSEC L, VAN DER HEIJDE D, MELIAN A et al.: Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64: 1563-7.
17. SYDNES OA: Comparison of piroxicam with indomethacin in ankylosing spondylitis: A double-blind crossover trial. Br J Clin Pract 1981; 35: 40-4.
18. CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2004-12.
19. DOUGADOS M, BOUMIER P, AMOR B: Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed) 1986; 293: 911-4.
20. ALTAN L, BINGOL U, KARAKOC Y et al.: Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30: 255-9.
21. RAMEY DR, WATSON DJ, YU C et al.: The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: An updated combined analysis. Curr Med Res Opin 2005; 21: 715-22.
22. DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one-year versus a 6-week non-steroidal anti-inflammatory drug trial. Rheumatology 1999; 38: 235-44.
23. VAN DER HEIJDE D, BARAF HS, RAMOS-REMUS C et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-15.
24. WANDERS A, VAN DER HEIJDE D, LANDEWE R et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65.
25. EL MIEDANY Y, YOUSSEF S, AHMED I et al.: The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101: 311-7.
26. SANDBORN WJ, STENSON WF, BRYNSKOV J et al.: Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4: 203-11.
27. ZOCHLING J, BRAUN J: Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S88-92.